New therapy helps tissue repair by targeting inflammation
A peptide nanofiber treatment helps heal chronic wounds by managing immune activity.
Researchers developed an active immunotherapy to restore tissue repair. This therapy targets interleukin-1 beta (IL-1β) to manage chronic inflammation.
The treatment uses a self-assembling peptide nanofiber called Coil29. This nanofiber elicits specific immune responses in wild-type and diabetic mice.
Chronic inflammation driven by sustained IL-1β signaling disrupts the resolution phase of tissue repair. IL-1β is a key upstream mediator that prolongs pro-inflammatory myeloid cell activation.
In a chronic wound model, the therapy accelerated re-epithelialization and enhanced tissue regeneration. It outperformed anti-IL-1β monoclonal antibodies.
The therapy suppressed macrophage activity and promoted M2-like polarization. This process may drive the enhanced wound re-epithelialization seen in immunized animals.
The findings highlight a targeted, regenerative therapy for healing chronic wounds. This therapy enriches the injury site with anti-IL-1β antibodies.
Key facts
- Coil29 is a self-assembling peptide nanofiber used for immunotherapy.
- The therapy promotes M2-like polarization in macrophages.
- The treatment accelerated re-epithelialization in a chronic wound model.